Organisation paid for research Program year 2025 Source: CMS Open Payments

Pinellas Medical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$259,619

31 payments

Through program year 2025, Pinellas Medical Research LLC is reported as receiving $259,619 in research payments, across 31 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $33,378 2
2024 Research $26,846 2
2023 Research $52,389 9
2022 Research $43,755 6
2021 Research $31,526 3
2020 Research $24,206 5
2019 Research $47,519 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $167,657 11 payments
  2. United Therapeutics Corporation $51,979 13 payments
  3. GlaxoSmithKline, LLC. $28,199 4 payments
  4. Sanofi US Services Inc. $6,200 1 payment
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $5,584 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod $96,471 4 payments
  2. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $51,979 13 payments
  3. The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do not achieve control with high dose inhaled corticosteroid ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibody therapy $40,133 2 payments
  4. A Phase Iib, Randomized (Stratified), Double-Blind (Sponsor Open), Par $23,723 2 payments
  5. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $19,797 1 payment
  6. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $10,838 2 payments
  7. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstruct $6,200 1 payment
  8. Pulmonary Rehabilitation and Nintedanib in IPF $5,584 2 payments
  9. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $4,476 2 payments
  10. A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $419 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record